Zai Lab (ZLAB) said Thursday that results from the ongoing phase 1a/1b trial of ZL-1310 in people with extensive-stage small cell lung cancer following at least one previous platinum-based chemotherapy treatment showed "promising" objective response rates and safety profile.
The objective response rate was 74% in all tested dose levels of ZL-1310 in people with the disease, the company said.
The firm showcased the data at the conference in Barcelona regarding the current phase 1a part of the research, which involves increasing the dosage of the drug in four different groups, including outcomes from a total of 25 participants.
"ZL-1310 anti-tumor activity was demonstrated across all dose levels," Zai Lab said.
Also, ZL-1310 was "well tolerated across all dose levels with the majority of treatment-emergent adverse events (TEAE) being Grade 1 or 2," the company said.
The shares of Zai Lab were rising past 15% in recent trading.
Price: 33.41, Change: +4.47, Percent Change: +15.45
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。